Clinical and Molecular Hepatology

"Jung Gil Park"

Special Issue

2025 KASL clinical practice guidelines for management of hepatitis C: Eun Sun Jang, Nae Yun Heo, Jae Yoon Jeong, Jung Gil Park, Do Seon Song, Eun Ju Cho, Chang Hun Lee, Jae Seung Lee, Jae Hyun Yoon, Seul Ki Han, Young Kul Jung, on behalf of the Korean Association for the Study of the Liver (KASL); Clin Mol Hepatol 2026;32(1):1-52.
Published online October 23, 2025; DOI: https://doi.org/10.3350/cmh.2025.0777

1,774 View
199 Download

Original Articles

Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial: Hyung Joon Yim, Yeon Seok Seo, Ji Hoon Kim, Won Kim, Young Kul Jung, Jae Young Jang, Sae Hwan Lee, Yun Soo Kim, Chang Wook Kim, Hyoung Su Kim, Jae-Jun Shim, Eun-Young Cho, In Hee Kim, Byung Seok Lee, Jeong-Hoon Lee, Byung Seok Kim, Jeong Won Jang, Hyun Woong Lee, Jung Hyun Kwon, Moon Young Kim, Do Seon Song, Jung Gil Park, Yoon Seok Lee, Eileen L. Yoon, Han Ah Lee, Seong Hee Kang, Jin Mo Yang; Clin Mol Hepatol 2025;31(3):810-822.
Published online January 17, 2025; DOI: https://doi.org/10.3350/cmh.2024.0819

Background/Aims
Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.
Methods
In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.
Result
s: The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF use before enrollment was 4.14 years. After 48 weeks, 100.0% and 98.5% patients in the BSV and TDF groups, respectively, met the primary endpoint (HBV DNA <20 IU/mL), demonstrating the non-inferior antiviral efficacy of BSV to TDF (95% confidence interval –0.01 to 0.04; P>0.999), with a predefined margin of –0.18. The mean percentage changes in estimated glomerular filtration rates were slightly better in the BSV group (1.67±11.73%) than in the TDF group (–1.24±11.02%). The BSV group showed a significant improvement in bone turnover biomarkers compared to the TDF group; accordingly, hip and spine bone mineral density increased in the BSV group.
Conclusions
In patients with CHB receiving long-term TDF, switching to BSV may improve renal and bone safety with non-inferior antiviral efficacy compared to that of maintaining TDF.

Citations

Citations to this article as recorded by

Correspondence to editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Hyung Joon Yim, Seong Hee Kang, Young Kul Jung, Jin Mo Yang
Clinical and Molecular Hepatology.2026; 32(1): e55. CrossRef
Besifovir: a viable option for long-term disease control in chronic hepatitis B: Editorial on “Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial”
Wai-Kay Seto
Clinical and Molecular Hepatology.2026; 32(1): 374. CrossRef
Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu
World Journal of Gastroenterology.2025;[Epub] CrossRef

11,090 View
179 Download
1 Web of Science
Crossref

Acute liver injury and Acute liver failure

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment: Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party; Clin Mol Hepatol 2024;30(3):388-405.
Published online April 11, 2024; DOI: https://doi.org/10.3350/cmh.2023.0563

Background/Aims
Quick sequential organ failure assessment (qSOFA) is believed to identify patients at risk of poor outcomes in those with suspected infection. We aimed to evaluate the ability of modified qSOFA (m-qSOFA) to identify high-risk patients among those with acutely deteriorated chronic liver disease (CLD), especially those with acute-onchronic liver failure (ACLF).
Methods
We used data from both the Korean Acute-on-Chronic Liver Failure (KACLiF) and the Asian Pacific Association for the Study of the Liver ACLF Research Consortium (AARC) cohorts. qSOFA was modified by replacing the Glasgow Coma Scale with hepatic encephalopathy, and an m-qSOFA ≥2 was considered high.
Result
s: Patients with high m-qSOFA had a significantly lower 1-month transplant-free survival (TFS) in both cohorts and higher organ failure development in KACLiF than those with low m-qSOFA (Ps<0.05). Subgroup analysis by ACLF showed that patients with high m-qSOFA had lower TFS than those with low m-qSOFA. m-qSOFA was an independent prognostic factor (hazard ratios, HR=2.604, 95% confidence interval, CI 1.353–5.013, P=0.004 in KACLiF and HR=1.904, 95% CI 1.484– 2.442, P<0.001 in AARC). The patients with low m-qSOFA at baseline but high m-qSOFA on day 7 had a significantly lower 1-month TFS than those with high m-qSOFA at baseline but low m-qSOFA on day 7 (52.6% vs. 89.4%, P<0.001 in KACLiF and 26.9% vs. 61.5%, P<0.001 in AARC).
Conclusions
Baseline and dynamic changes in m-qSOFA may identify patients with a high risk of developing organ failure and short-term mortality among CLD patients with acute deterioration.

Citations

Citations to this article as recorded by

Acute-on-chronic liver failure: pathophysiological mechanisms and clinical management
S. K. Sarin, Ashok Choudhury, Anupam Kumar, Nadim Mahmud, G. H. Lee, Qin Ning, Soek-Siam Tan, Kessarin Thanapirom, Vinod Arora, Nobuaki Nakayama, Jun Li, Constantine J. Karvellas
Nature Reviews Gastroenterology & Hepatology.2026;[Epub] CrossRef
Outcomes of Highly Urgent ABO-Incompatible Living Donor Liver Transplantation in National Databases
Jongman Kim, Sang Jin Kim, Boram Park, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Seung Heui Hong, Soon-Young Kim, Jungbun Park, Youngwon Hwang, Dong-Hwan Jung
Journal of Korean Medical Science.2026;[Epub] CrossRef
Emergency living donor liver transplantation
Jongman Kim
Annals of Liver Transplantation.2025; 5(1): 27. CrossRef
Oral Branched-Chain Amino Acids as a Cost-Effective Option for Managing Hepatic Encephalopathy
Hankil Lee, Sang Hoon Ahn, Beom Kyung Kim
Yonsei Medical Journal.2025; 66(11): 713. CrossRef
Living versus deceased donor liver transplantation in highly urgent patients using Korean national data
Jongman Kim, Sang Jin Kim, Kyunga Kim, YoungRok Choi, Geun Hong, Jun Yong Park, Young Seok Han, Nam-Joon Yi, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 115. CrossRef
Predicting risk factors for waiting mortality in adult emergent living donor liver transplantation based on Korean national data
Sang Jin Kim, Jongman Kim, Kyunga Kim, Soon-Young Kim, Jung-Bun Park, Youngwon Hwang, Dong-Hwan Jung
Annals of Liver Transplantation.2025; 5(2): 107. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment”
Do Seon Song, Dong Joon Kim
Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Modified quick-SOFA score: Can it enhance prognostic assessment for hospitalized patients with chronic liver diseases?: Editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure a
Simone Incicco, Salvatore Piano
Clinical and Molecular Hepatology.2024; 30(4): 695. CrossRef
Revisiting septic shock in cirrhosis: a call for personalized management
Vishnu Girish, Rakhi Maiwall
Expert Review of Gastroenterology & Hepatology.2024; 18(12): 795. CrossRef

8,389 View
143 Download
10 Web of Science
Crossref

COVID-19

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea: Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park; Clin Mol Hepatol 2020;26(4):562-576.
Published online October 1, 2020; DOI: https://doi.org/10.3350/cmh.2020.0126

Background/Aims
Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved.

Methods
A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed.

Result
s: Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02;P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients.

Conclusions
This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.

Citations

Citations to this article as recorded by

Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis
Danyang Dai, Pedro Franca Gois, Digby Simpson, Souhayel Hedfi, Sally Shrapnel, Jason Donald Pole
Journal of Global Health.2025;[Epub] CrossRef
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Levente Zsichla, Viktor Müller
Viruses.2023; 15(1): 175. CrossRef
SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups
George D Liatsos
World Journal of Gastroenterology.2023; 29(16): 2397. CrossRef
COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
Mohammad T. Imam, Ziyad S. Almalki, Abdullah R. Alzahrani, Saeed S. Al-Ghamdi, Alaa H. Falemban, Ibrahim M. Alanazi, Naiyer Shahzad, Munira Muhammad Alrooqi, Qaiser Jabeen, Imran Shahid
International Immunopharmacology.2023; 121: 110439. CrossRef
Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database
Jung Wan Choe, Young Kul Jung, Hyung Joon Yim, Gi Hyeon Seo
Journal of Korean Medical Science.2022;[Epub] CrossRef
Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
Pathogens.2022; 11(5): 563. CrossRef
COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis
Ramya Nagarajan, Yuvaraj Krishnamoorthy, Sathish Rajaa, Vishnu Shankar Hariharan
Preventing Chronic Disease.2022;[Epub] CrossRef
Forms of cholangitis to be considered after SARS-CoV-2 infection
Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
Clinical and Molecular Hepatology.2022; 28(4): 929. CrossRef
A systems biology approach for investigating significantly expressed genes among COVID-19, hepatocellular carcinoma, and chronic hepatitis B
Babak Sokouti
Egyptian Journal of Medical Human Genetics.2022;[Epub] CrossRef
Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
Clinical and Molecular Hepatology.2022; 28(4): 926. CrossRef
Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19
Min-Kyu Kang, Yu-Rim Lee, Jeung-Eun Song, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Jung-Gil Park, Soo-Young Park
Diagnostics.2022; 12(9): 2255. CrossRef
The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies
Maryam Afraie, Pardis Mohammadzedeh, Mobin Azami, Sorour Khateri, Kamran Zamani, Farhad Moradpour, Yousef Moradi
The Clinical Respiratory Journal.2022; 16(12): 777. CrossRef
COVID-19 With Preexisting Hypercoagulability Digestive Disease
Mingshan Jiang, Jingxi Mu, Silan Shen, Hu Zhang
Frontiers in Medicine.2021;[Epub] CrossRef
A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence
Jasjit S. Suri, Sushant Agarwal, Suneet K. Gupta, Anudeep Puvvula, Mainak Biswas, Luca Saba, Arindam Bit, Gopal S. Tandel, Mohit Agarwal, Anubhav Patrick, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Paramjit S. Chadha, Amer M. Johri, J. M
Computers in Biology and Medicine.2021; 130: 104210. CrossRef
COVID‐19 in hospitalized liver transplant recipients: An early systematic review and meta‐analysis
Kumar Jayant, Isabella Reccia, Francesco Virdis, Jordan S. Pyda, Piotr J. Bachul, Diego di Sabato, Rolf N. Barth, John Fung, Talia Baker, Piotr Witkowski
Clinical Transplantation.2021;[Epub] CrossRef
Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic
Yu Rim Lee
The Korean Journal of Gastroenterology.2021; 77(4): 156. CrossRef
Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives
Hung-Yuan Su, Yin-Chou Hsu
World Journal of Clinical Cases.2021; 9(13): 2951. CrossRef
Italian association for the study of the liver position statement on SARS-CoV2 vaccination
Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo
Digestive and Liver Disease.2021; 53(6): 677. CrossRef
Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
Wattana Leowattana
World Journal of Virology.2021; 10(3): 86. CrossRef
Impact of COVID-19 on liver
Yu-Jang Su, Chen-Wang Chang, Ming-Jen Chen, Yen-Chun Lai
World Journal of Clinical Cases.2021; 9(27): 7998. CrossRef
Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
Clinical and Molecular Hepatology.2021; 27(4): 515. CrossRef
Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
Paul Middleton, Catherine Hsu, Mark P Lythgoe
BMJ Open Gastroenterology.2021; 8(1): e000739. CrossRef
Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
Jeong Eun Song, Min Kyu Kang, Yu Rim Lee, Chang Hyeong Lee, Jung Gil Park, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jae Seok Hwang, Byoung Kuk Jang, Won Young Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim
Gut and Liver.2021; 15(4): 606. CrossRef
Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients
Cyriac Abby Philips, Mohamed Rela, Arvinder Singh Soin, Subhash Gupta, Sudhindran Surendran, Philip Augustine
Journal of Clinical and Translational Hepatology.2021; 000(000): 000. CrossRef

11,863 View
190 Download
23 Web of Science
Crossref

Hepatic neoplasm

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy: Jung Gil Park; Clin Mol Hepatol 2015;21(3):287-294.
Published online September 30, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.3.287

Abstract
PDF

Background/Aims

Sorafenib is currently the sole molecular targeted agent that improves overall survival in advanced hepatocellular carcinoma (HCC). Despite the efficacy of sorafenib, the response rate varies in patients with advanced HCC. We retrospectively analyzed a series of Korean patients with advanced HCC with complete remission (CR) after sorafenib therapy.

Methods

In total, 523 patients with advanced HCC were treated with sorafenib in 3 large tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who experienced CR after sorafenib monotherapy, and their medical records and follow-up data were analyzed. The tumor response and recurrence rates were assessed by radiologic study, based on modified response evaluation criteria in solid tumors.

Results

Seven patients with advanced HCC experienced CR after sorafenib therapy. The median time to tumor disappearance and the median disease-free survival time were 3 months and 9 months, respectively. HCC recurrence was identified in three cases (42.9%). Of these, two patients discontinued sorafenib before or after achieving CR and the other patient continued sorafenib after achieving CR. HCC recurred at 3, 10, and 42 months after CR in these three patients. Three patients needed dose reduction for toxicity and adverse events.

Conclusions

Though CR was achieved after sorafenib therapy in patients with advanced HCC, the recurrence rate was relatively high. Subsequent strategies to reduce a chance of recurrence after sorafenib therapy are required to investigate.

Citations

Citations to this article as recorded by

Five-year complete remission of super-giant hepatocellular carcinoma with hepatectomy followed by sorafenib plus camrelizumab: A case report
Xiao-Qin Zheng, Li-Bo Sun, Wen-Jie Jin, Hui Liu, Wen-Yan Song, Hui Xu, Ju-Shan Wu, Xiao-Jun Wang, Chun-Yan Gou, Hui-Guo Ding
World Journal of Gastrointestinal Surgery.2025;[Epub] CrossRef
TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects
Wanting Zeng, Wei Zhu, Guosheng Yuan, Jinzhang Chen, Zhanhui Wang, Jinlin Hou, De-Ke Jiang
Cancer Immunology, Immunotherapy.2025;[Epub] CrossRef
Efficacy and safety analysis of transarterial chemoembolization and transarterial radioembolization in advanced hepatocellular carcinoma descending hepatectomy
Rui Feng, De-Xin Cheng, Tao Song, Long Chen, Kai-Ping Lu
World Journal of Gastrointestinal Surgery.2023; 15(4): 687. CrossRef
Long-term follow-up of complete remission in a patient with advanced hepatocellular carcinoma treated with sorafenib: a case report
Gordan Adžić, Juraj Prejac, Stjepko Pleština
Frontiers in Oncology.2023;[Epub] CrossRef
Long-term survival with sorafenib-based multidisciplinary treatment for Vp4 hepatocellular carcinoma: a case report
Hibiki Narita, Hideto Kawaratani, Akihiko Shibamoto, Soichi Takeda, Takahiro Ozutsumi, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Norihisa Nishimura, Daisuke Hokuto, Masayuki Sho, Hitoshi Yoshiji
Clinical Journal of Gastroenterology.2022; 15(5): 953. CrossRef
Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis
Hai-Yi Long, Tong-Yi Huang, Xiao-Yan Xie, Jian-Ting Long, Bao-Xian Liu
World Journal of Clinical Cases.2021; 9(21): 5754. CrossRef
Identification of the Response-Related Biomarker of Bimonthly Hepatic Arterial Infusion Chemotherapy
Kei Moriya, Tadashi Namisaki, Hiroaki Takaya, Kosuke Kaji, Hideto Kawaratani, Naotaka Shimozato, Yasuhiko Sawada, Akitoshi Douhara, Shinya Sato, Masanori Furukawa, Koh Kitagawa, Takemi Akahane, Hitoshi Yoshiji
Journal of Clinical Medicine.2021; 10(4): 629. CrossRef
Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma
Morihiko Ishizaki, Masaki Kaibori, Hideyuki Matsushima, Hisashi Kosaka, Kosuke Matsui, Mitsugu Sekimoto
Clinical Journal of Gastroenterology.2021; 14(6): 1700. CrossRef
Sorafenib Treatment has the Potential to Downstage Advanced Hepatocellular Carcinoma before Liver Resection
Alessandra Bertacco, Alessandro Vitale, Claudia Mescoli, Umberto Cillo
Personalized Medicine.2020; 17(2): 83. CrossRef
Long-term sustained complete response with off-therapy to sorafenib in advanced hepatocellular carcinoma: a case report
Takeshi Koujima, Yoshikatsu Endo, Takeharu Yamamoto, Toshifumi Tada, Kazuhiko Morii, Shinichiro Nakamura, Kyohei Kai
Kanzo.2020; 61(5): 255. CrossRef
Effectiveness of sorafenib dose modifications on treatment outcome of hepatocellular carcinoma: Analysis in real‐life settings
Kwon Yong Tak, Hee Chul Nam, Jong Young Choi, Seung Kew Yoon, Chang Wook Kim, Hee Yeon Kim, Sung Won Lee, Hae Lim Lee, U Im Chang, Do Seon Song, Jin Mo Yang, Jung Hyun Kwon, Sun Hong Yoo, Pil Soo Sung, Sang Wook Choi, Myeong Jun Song, Seok Hwan Kim, Jeong
International Journal of Cancer.2020; 147(7): 1970. CrossRef
Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively
Yung‐Ning Huang, Yang‐Bor Lu, Sheng‐Nan Lu
The Kaohsiung Journal of Medical Sciences.2019; 35(1): 63. CrossRef
Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling
Zhang-Bin Tan, Hui-Jie Fan, Yu-Ting Wu, Ling-Peng Xie, Yi-Ming Bi, Hong-Lin Xu, Hong-Mei Chen, Jun Li, Bin Liu, Ying-Chun Zhou
Journal of Ethnopharmacology.2019; 232: 62. CrossRef
Liver Transplantation after Successful Downstaging with Hepatic Arterial Infusion Chemotherapy in a Patient with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus
Hee Chul Nam, Pil Soo Sung, Ho Jong Chun, Dong Goo Kim, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon
Journal of Liver Cancer.2019; 19(1): 64. CrossRef
Antineoplastic properties of zafirlukast against hepatocellular carcinoma via activation of mitochondrial mediated apoptosis
Pranesh Kumar, Aakriti Agarwal, Ashok K. Singh, Anurag Kumar Gautam, Sreemoyee Chakraborti, Umesh Kumar, Dinesh Kumar, Bolay Bhattacharya, Parthasarathi Panda, Biswajit Saha, Tabish Qidwai, Biswanath Maity, Sudipta Saha
Regulatory Toxicology and Pharmacology.2019; 109: 104489. CrossRef
Complete Response Using Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma with Multiple Lymph Node and Bone Metastases: A Case Report
Norihiro NOMURA, Takayoshi ITO, Hiroki SHINOHARA, Nobukazu SHIMA, Masashi SATOU, Dai SAKUMA, Junichi EGUCHI, Naoyuki URAGAMI, Yoshio DEGUCHI, Noboru YOKOYAMA, Haruhiro INOUE
The Showa University Journal of Medical Sciences.2019; 31(4): 373. CrossRef
Novel fused oxazepino-indoles (FOIs) attenuate liver carcinogenesis via IL-6/JAK2/STAT3 signaling blockade as evidenced through data-based mathematical modeling
Ashok K. Singh, Archana Singh Bhadauria, Umesh Kumar, Vinit Raj, Vimal Maurya, Dinesh Kumar, Biswanath Maity, Anand Prakash, Arnab De, Amalesh Samanta, Sudipta Saha
Life Sciences.2018; 201: 161. CrossRef
Long-term prognostic impact of osteopontin and Dickkopf-related protein 1 in patients with hepatocellular carcinoma after hepatectomy
Hyerim Byeon, Seung Duk Lee, Eun-Kyung Hong, Dong Eun Lee, Bo Hyun Kim, Yunsung Seo, Jungnam Joo, Sung-Sik Han, Seong Hoon Kim, Sang-Jae Park
Pathology - Research and Practice.2018; 214(6): 814. CrossRef
Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer
Sarah Yoon, Eun-Ju Lee, Ji-Hye Choi, Taek Chung, Do Young Kim, Jong-Yeop Im, Myung-Ho Bae, Jung-Hee Kwon, Hyuk-Hoon Kim, Hyung Chul Kim, Young Nyun Park, Hee-Jung Wang, Hyun Goo Woo
Oncogene.2018; 37(32): 4443. CrossRef
Novel Indole-fused benzo-oxazepines (IFBOs) inhibit invasion of hepatocellular carcinoma by targeting IL-6 mediated JAK2/STAT3 oncogenic signals
Ashok K. Singh, Archana S. Bhadauria, Umesh Kumar, Vinit Raj, Amit Rai, Pranesh Kumar, Amit K. Keshari, Dinesh Kumar, Biswanath Maity, Sneha Nath, Anand Prakash, Sudipta Saha
Scientific Reports.2018;[Epub] CrossRef
Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis
Jong Hwan Choi, Woo Jin Chung, Si Hyun Bae, Do Seon Song, Myeong Jun Song, Young Seok Kim, Hyung Joon Yim, Young Kul Jung, Sang Jun Suh, Jun Yong Park, Do Young Kim, Seung Up Kim, Sung Bum Cho
Cancer Chemotherapy and Pharmacology.2018; 82(3): 469. CrossRef
Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?
Matthias Pinter, Wolfgang Sieghart
memo - Magazine of European Medical Oncology.2018; 11(3): 185. CrossRef
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury
Sofie Martens, Manhyung Jeong, Wulf Tonnus, Friederike Feldmann, Sam Hofmans, Vera Goossens, Nozomi Takahashi, Jan Hinrich Bräsen, Eun-Woo Lee, Pieter Van der Veken, Jurgen Joossens, Koen Augustyns, Simone Fulda, Andreas Linkermann, Jaewhan Song, Peter Va
Cell Death & Disease.2017; 8(6): e2904. CrossRef
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation
Hye Won Lee, Hyun Soo Kim, Seung Up Kim, Do Young Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Mi Young Jeon, Ja Yoon Heo, Soo Young Park, Yu Rim Lee, Sun Kyung Jang, Su Hyun Lee, Se Young Jang, Won Young Tak, Kwang-Hyub Han
Gut and Liver.2017; 11(5): 693. CrossRef
Long-term follow-up of complete remission of advanced hepatocellular carcinoma following sorafenib therapy: A case report
Jung Gil Park, Won Young Tak, Soo Young Park, Young Oh Kweon, Se Young Jang, Soo Hyun Lee, Yu Rim Lee, Sun Kyung Jang, Keun Hur, Heon Ju Lee
Oncology Letters.2017; 14(4): 4853. CrossRef
Outcomes of metastatic spinal cord compression secondary to primary hepatocellular carcinoma with multidisciplinary treatments
Shaohui He, Haifeng Wei, Yifei Ma, Jian Zhao, Wei Xu, Jianru Xiao
Oncotarget.2017; 8(26): 43439. CrossRef
17β-estradiol exerts anticancer effects in anoikis-resistant hepatocellular carcinoma cell lines by targeting IL-6/STAT3 signaling
Seulki Lee, Minjong Lee, Jong Bin Kim, Ara Jo, Eun Ju Cho, Su Jong Yu, Jeong-Hoon Lee, Jung-Hwan Yoon, Yoon Jun Kim
Biochemical and Biophysical Research Communications.2016; 473(4): 1247. CrossRef
Sorafenib

Reactions Weekly.2016; 1599(1): 202. CrossRef
Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells
Yuri Cho, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Yoon Jun Kim, Chung Yong Kim, Jung-Hwan Yoon
Biomedicine & Pharmacotherapy.2016; 83: 607. CrossRef
Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma
Xiangting Qiu, Xinhua Wang, Yucui Song, Lingling Chen
Digestive Diseases and Sciences.2016; 61(12): 3513. CrossRef

11,961 View
80 Download
28 Web of Science
Crossref

Viral hepatitis

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy: Jung Gil Park, Soo Young Park; Clin Mol Hepatol 2015;21(3):242-248.
Published online September 30, 2015; DOI: https://doi.org/10.3350/cmh.2015.21.3.242

Abstract
PDF

Background/Aims

We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed a suboptimal response to LAM and ADV combination therapy.

Methods

We reviewed 63 CHB patients with genotypic resistance to LAM who showed a suboptimal response to LAM and ADV combination therapy. Among these patients, 30 were treated with ETV + ADV and 33 were treated with ETV + TDF for 12 months.

Results

The only baseline characteristic that differed significantly between the two groups was the ETV resistance profile. The rate of a virologic response [serum hepatitis B virus (HBV) DNA level of <20 IU/mL] was significant higher for ETV+TDF than for ETV+ADV over 12 months (57.6% vs. 23.3%, P=0.006, at 6 months; 84.8% vs. 26.7%, P<0.001, at 12 months). The probability of a virologic response was significantly increased in ETV+TDF (P<0.001, OR=54.78, 95% CI=7.15-419.54) and decreased in patients with higher baseline viral loads (P=0.001, OR=0.18, 95% CI=0.07-0.50) in multivariate analysis. No serious adverse event occurred during the study period.

Conclusions

In patients with CHB who showed a suboptimal response to LAM and ADV combination therapy, ETV+TDF was superior to ETV+ADV in achieving a virologic response regardless of the HBV resistance profile. Further large-scale and long-term follow-up prospective studies are needed to explain these results.

Citations

Citations to this article as recorded by

Tenofovir plus entecavir combination therapy for chronic hepatitis B with nucleos(t)ide analogue failure
Bengü TATAR, Şükran KÖSE
The European Research Journal.2020; 6(4): 270. CrossRef
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
Hyun Young Woo, Jun Yong Park, Si Hyun Bae, Chang Wook Kim, Jae Young Jang, Won Young Tak, Dong Joon Kim, In Hee Kim, Jeong Heo, Sang Hoon Ahn
Clinical and Molecular Hepatology.2020; 26(3): 352. CrossRef
Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
Hyung Joon Yim
Clinical and Molecular Hepatology.2016; 22(2): 238. CrossRef
Biological Antivirals for Treatment of Adenovirus Infections
Katrin Schaar, Carsten Röger, Tanja Pozzuto, Jens Kurreck, Sandra Pinkert, Henry Fechner
Antiviral Therapy.2016; 21(7): 559. CrossRef